Your browser doesn't support javascript.
loading
Seasonal influenza vaccine performance and the potential benefits of mRNA vaccines.
Russell, Colin A; Fouchier, Ron A M; Ghaswalla, Parinaz; Park, Yoonyoung; Vicic, Nevena; Ananworanich, Jintanat; Nachbagauer, Raffael; Rudin, Deborah.
Afiliación
  • Russell CA; Department of Medical Microbiology & Infection Prevention, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
  • Fouchier RAM; Department of Viroscience, Erasmus Medical Center, Rotterdam, the Netherlands.
  • Ghaswalla P; Moderna, Inc., Cambridge, MA, USA.
  • Park Y; Moderna, Inc., Cambridge, MA, USA.
  • Vicic N; Moderna, Inc., Cambridge, MA, USA.
  • Ananworanich J; Moderna, Inc., Cambridge, MA, USA.
  • Nachbagauer R; Moderna, Inc., Cambridge, MA, USA.
  • Rudin D; Moderna, Inc., Cambridge, MA, USA.
Hum Vaccin Immunother ; 20(1): 2336357, 2024 Dec 31.
Article en En | MEDLINE | ID: mdl-38619079
ABSTRACT
Influenza remains a public health threat, partly due to suboptimal effectiveness of vaccines. One factor impacting vaccine effectiveness is strain mismatch, occurring when vaccines no longer match circulating strains due to antigenic drift or the incorporation of inadvertent (eg, egg-adaptive) mutations during vaccine manufacturing. In this review, we summarize the evidence for antigenic drift of circulating viruses and/or egg-adaptive mutations occurring in vaccine strains during the 2011-2020 influenza seasons. Evidence suggests that antigenic drift led to vaccine mismatch during four seasons and that egg-adaptive mutations caused vaccine mismatch during six seasons. These findings highlight the need for alternative vaccine development platforms. Recently, vaccines based on mRNA technology have demonstrated efficacy against SARS-CoV-2 and respiratory syncytial virus and are under clinical evaluation for seasonal influenza. We discuss the potential for mRNA vaccines to address strain mismatch, as well as new multi-component strategies using the mRNA platform to improve vaccine effectiveness.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vacunas contra la Influenza / Virus Sincitial Respiratorio Humano / Gripe Humana Límite: Humans Idioma: En Revista: Hum Vaccin Immunother / Hum. vaccin. immunother. (Online) / Human vaccines & immunotherapeutics (Online) Año: 2024 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vacunas contra la Influenza / Virus Sincitial Respiratorio Humano / Gripe Humana Límite: Humans Idioma: En Revista: Hum Vaccin Immunother / Hum. vaccin. immunother. (Online) / Human vaccines & immunotherapeutics (Online) Año: 2024 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Estados Unidos